JAK inhibition during the early phase of SARS-CoV-2 infection worsens kidney injury by suppressing endogenous antiviral activity in mice

Am J Physiol Renal Physiol. 2024 Jun 1;326(6):F931-F941. doi: 10.1152/ajprenal.00011.2024. Epub 2024 Apr 18.

Abstract

Coronavirus disease 2019 (COVID-19) induces respiratory dysfunction as well as kidney injury. Although the kidney is considered a target organ of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and affected by the COVID-19-induced cytokine storm, the mechanisms of renal reaction in SARS-CoV-2 infection are unknown. In this study, a murine COVID-19 model was induced by nasal infection with mouse-adapted SARS-CoV-2 (MA10). MA10 infection induced body weight loss along with lung inflammation in mice 4 days after infection. Serum creatinine levels and the urinary albumin/creatinine ratio increased on day 4 after MA10 infection. Measurement of the urinary neutrophil gelatinase-associated lipocalin/creatinine ratio and hematoxylin and eosin staining revealed tubular damage in MA10-infected murine kidneys, indicating kidney injury in the murine COVID-19 model. Interferon (IFN)-γ and interleukin-6 upregulation in the sera of MA10-infected mice, along with the absence of MA10 in the kidneys, implied that the kidneys were affected by the MA10 infection-induced cytokine storm rather than by direct MA10 infection of the kidneys. RNA-sequencing analysis revealed that antiviral genes, such as the IFN/Janus kinase (JAK) pathway, were upregulated in MA10-infected kidneys. Upon administration of the JAK inhibitor baricitinib on days 1-3 after MA10 infection, an antiviral pathway was suppressed, and MA10 was detected more frequently in the kidneys. Notably, JAK inhibition upregulated the hypoxia response and exaggerated kidney injury. These results suggest that endogenous antiviral activity protects against SARS-CoV-2-induced kidney injury in the early phase of infection, providing valuable insights into the pathogenesis of COVID-19-associated nephropathy.NEW & NOTEWORTHY Patients frequently present with acute kidney injury or abnormal urinary findings after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we investigated how the kidneys respond during SARS-CoV-2 infection using a murine coronavirus disease 2019 (COVID-19) model and showed that Janus kinase-mediated endogenous antiviral activity protects against kidney injury in the early phase of SARS-CoV-2 infection. These findings provide valuable insights into the renal pathophysiology of COVID-19.

Keywords: JAK; SARS-CoV-2; antiviral activity; baricitinib; kidney injury.

MeSH terms

  • Acute Kidney Injury / etiology
  • Acute Kidney Injury / metabolism
  • Acute Kidney Injury / virology
  • Animals
  • Antiviral Agents / pharmacology
  • Antiviral Agents / therapeutic use
  • Azetidines / pharmacology
  • Azetidines / therapeutic use
  • COVID-19 Drug Treatment
  • COVID-19* / complications
  • Disease Models, Animal
  • Janus Kinase Inhibitors* / pharmacology
  • Janus Kinase Inhibitors* / therapeutic use
  • Janus Kinases / antagonists & inhibitors
  • Janus Kinases / metabolism
  • Kidney / drug effects
  • Kidney / metabolism
  • Kidney / pathology
  • Kidney / virology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Purines* / pharmacology
  • Pyrazoles* / pharmacology
  • SARS-CoV-2*
  • Sulfonamides* / pharmacology

Substances

  • Janus Kinase Inhibitors
  • baricitinib
  • Sulfonamides
  • Purines
  • Pyrazoles
  • Azetidines
  • Janus Kinases
  • Antiviral Agents